Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 8/20 | 0.41 |
| ▸ | HTR1D | P28221 | 8/20 | 0.41 |
| ▸ | HTR1B | P28222 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 5/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP1 | P07148 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 2/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930620 | 0.86 | HSP90AA1 (0.42) | MTNR1AHTR1AHTR1DHTR1BKDM4E | |
| SCHEMBL931385 | 0.83 | HSP90AA1 (0.37) | KDM4EALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL977297 | 0.81 | IDH1 (0.38) | MTNR1AHSP90AA1HSP90AB1 | |
| SCHEMBL931152 | 0.78 | HSP90AA1 (0.44) | MTNR1AHTR1AHTR1DHTR1BKDM4E | |
| SCHEMBL931450 | 0.77 | ESR1 (0.36) | KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL929862 | 0.77 | HSP90AA1 (0.38) | KDM4EALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL940774 | 0.76 | HSP90AA1 (0.47) | MTNR1AHTR1AHTR1DHTR1BKDM4E | |
| SCHEMBL1343239 | 0.76 | MTNR1A (0.41) | MTNR1AHTR1AHTR1DHTR1BKDM4E | |
| SCHEMBL930607 | 0.75 | L3MBTL1 (0.39) | KDM4EALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL930650 | 0.74 | MAPT (0.40) | KDM4EALDH1A1HSP90AA1HSP90AB1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | claimed |
| WO-2011146801-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-24 | — | — | WO | claimed |
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9090569-B2 | Triazone compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140363830-A1 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8901308-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130172333-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8362055-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120330009-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2012-12-27 | — | — | US | disclosed |
| US-20110105749-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-05-05 | — | — | US | disclosed |
| EP-2298748-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295416-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009397-A1 | TRIAZONE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-01-13 | — | — | US | disclosed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 3481/4885HTR1A 2967/4885HTR1D 3475/4885 |
| US-20120330009-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | MTNR1A 4246/4885HTR1A 4045/4885HTR1D 4145/4885 |
| US-20130172333-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 4694/4885HTR1A 3768/4885HTR1D 4240/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 3489/4885HTR1A 2644/4885HTR1D 3215/4885 |
| US-20110009397-A1 | TRIAZONE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AB2P, HSP90AA1 | MTNR1A 4363/4885HTR1A 3922/4885HTR1D 4104/4885 |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 4694/4885HTR1A 3768/4885HTR1D 4240/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | MTNR1A 4728/4885HTR1A 4304/4885HTR1D 4402/4885 |
| US-20110105749-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | MTNR1A 4246/4885HTR1A 4045/4885HTR1D 4145/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | MTNR1A 3898/4885HTR1A 3264/4885HTR1D 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.